ONO-2506. Ono.

Article Details

Citation
Copy to clipboard

de Paulis T

ONO-2506. Ono.

Curr Opin Investig Drugs. 2003 Jul;4(7):863-7.

PubMed ID
14619409 [ View in PubMed
]
Abstract

ONO-2506 is an enantiomeric, three carbon atom homolog of valproic acid under development by ONO Pharmaceutical for the potential treatment of stroke, as well as Alzheimer's and Parkinson's disease. The injectable formulation (Proglia) is undergoing phase II trials in the US and Japan for acute-phase cerebral infarction, and the oral formulation (Cereact) is in phase I trials in the UK for Alzheimer's disease (AD) and Parkinson's disease (PD). Japanese and European phase I trials for AD, PD and amyotropic lateral sclerosis (ALS) had commenced by March 2002 and phase II trials for ALS are underway in Europe.

DrugBank Data that Cites this Article

Drugs